Over the past ten years, sodium-glucose cotransporter-2 (SGLT2) inhibitors have made a significant impact in treating type 2 diabetes, heart failure, and chronic kidney disease. Recent studies suggest that these drugs may also benefit patients with rheumatologic diseases such as gout and systemic lupus erythematosus (SLE). These findings raise the potential for expanding the use of SGLT2 inhibitors in rheumatology, but they are not currently approved for this usage. However, patients with comorbidities such as diabetes or chronic kidney disease may already be eligible for SGLT2 inhibitors. Studies have shown that these drugs might be beneficial for gout, systemic lupus erythematosus, and lupus nephritis but more research is required.
Source link
SGLT2 Inhibitors Begin to Show Potential in Rheumatology
